Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy
|ClinicalTrials.gov Identifier: NCT00165204|
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : December 21, 2007
|Condition or disease||Intervention/treatment||Phase|
|Menopause Postmenopausal Bone Loss Breast Cancer||Drug: Tibolone||Phase 2|
Women interested in participating in this study will be allowed to use hormones to manage symptoms for up to 3 months before beginning the study. Those choosing not to take hormones may enroll in the study immediately.
All women will have a baseline mammogram, breast examination, and bone study density performed, along with blood and urine analysis for measurement of bone markers. They will also be asked to take a questionnaire.
Patients will take either tibolone or placebo once daily for 1 year. Neither the patient or the physician will be aware of which treatment a woman is taking during the study.
Patients will return at 6 and 12 months to have a physical examination, blood work, urine collection and bone studies. At one year, a repeat mammogram will be performed. There are also some questionnaires asking about menopause symptoms that will be performed at intervals during the study.
It is also recommended that patients take calcium and vitamin D throughout the study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Factorial Assignment|
|Official Title:||A Randomized Study of the Effects of Tibolone on Bone Density, Menopause Symptoms and Breast Density in High Risk Women After Prophylactic Oophorectomy|
|Study Start Date :||April 2004|
|Primary Completion Date :||March 2006|
|Study Completion Date :||March 2006|
- To compare bone mineral density and markers of bone turnover following oophorectomy in patients receiving tibolone versus placebo
- To compare changes in menopausal symptoms and mammographic breast density in women taking tibolone to women taking placebo
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00165204
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Dana-Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Judy Garber, MD, MPH||Dana-Farber Cancer Institute|